A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma
Study Details
Study Description
Brief Summary
The aim of this study was to establish and optimize the imaging method of [68Ga]Ga-NOTA-RG2, as well as its physiological and pathological distribution characteristics, and on this basis to evaluate the diagnostic efficacy of the above imaging agents in patients with hepatocellular carcinoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: patients with Hepatocellular Carcinoma Subjects were recruited from thoracic surgery. |
Radiation: [68Ga]Ga-NOTA-RG2 PET Imaging
Intravenous injection of 1.8 MBq [0.05MCi]/kg of [68Ga]Ga-NOTA-RG2 in a single dose.
|
Outcome Measures
Primary Outcome Measures
- Complete PET imaging [90mins from time of injection]
To assess the sensitivity and specificity of diagnosing HCC using [68Ga]Ga-NOTA-RG2.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Hepatocellular carcinoma patients
-
Age between 18 and 65 years old, gender is not limited.
-
Patients with suspicious intrahepatic spaces detected by MR and considered to be hepatocellular carcinoma with AFP>200 ug/L who have not undergone surgery.
-
Patients with hepatocellular carcinoma confirmed by puncture pathology
-
Written informed consent must be signed by the subject or his/her legal guardian or caregiver.
-
Willingness and ability to cooperate with all programs of the study.
Exclusion Criteria:
- Subjects meeting any of the following criteria will be excluded from the study:
-
Patients receiving anti-tumor therapy prior to the PET/CT scan.
-
Suffering from severe other neurological disorders, or gastrointestinal, cardiovascular, hepatic, renal, hematologic, respiratory, immunodeficiency, and other serious diseases.
-
Alternative subjects with conditions that contraindicate PET/CT scanning. This includes, but is not limited to, elevated blood glucose that is not effectively controlled; pregnant, lactating, or breastfeeding women; those who are unable to receive repeated intravenous injections; those who may be hypersensitive to the drug and its components (including a history of severe allergies or anaphylactic reactions, especially to the drug being examined); and hermetic phobias.
-
Within the past year, have participated in other research protocols or clinical care, in addition to the radiation exposure expected from participation in this clinical study, which has resulted in radiation exposure in excess of an effective dose of 50 mSv.
-
Alternative subjects have undergone major surgery within the last 3 months; experimental drug or device therapy (of uncertain efficacy or safety) within 1 month
-
The alternate subject has any clinical condition that, in the opinion of the Sponsor of this study, may cause or has the potential to cause harm from this agent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Huashan Hospital | Shanghai | China | 200040 |
Sponsors and Collaborators
- Huashan Hospital
Investigators
- Principal Investigator: Fang Xie, PhD, Huashan Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KY2023-544